Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Xunfei Healthcare Technology (XHT HK)
Watchlist
17
Analysis
Health Care
•
China
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
China Merchants China Direct Investments
•
11 Nov 2024 15:19
CMCDI (133 HK)'s EGM Double-Header
If shareholders want exposure to CMB and iFlytek, they can buy directly, as opposed to a heavily discounted illiquid name. CMCDI's large NAV...
David Blennerhassett
Follow
597 Views
Share
bullish
•
China Merchants China Direct Investments
•
22 Oct 2024 16:20
CMCDI (133 HK): Concessions Don't Go Far Enough
If small, illiquid names, with a activism angle are your bent, get involved in this deep valued closed-end fund around here.
David Blennerhassett
Follow
701 Views
Share
bullish
•
China Merchants China Direct Investments
•
02 Oct 2024 15:00
CMCDI (133 HK)'s Proposals Light On Detail
If small, illiquid names, with a activism angle are your bag, get involved. Expect the investment management fee vote later this year to get voted...
David Blennerhassett
Follow
611 Views
Share
bullish
•
China Merchants China Direct Investments
•
28 Jun 2024 07:00
CMCDI (133 HK): Buybacks And Management Fees Into Focus
CMCDI remains cheap. I think a buyback is a distinct possibility. And changes to the management agreement have to occur within the next few months.
David Blennerhassett
Follow
574 Views
Share
bullish
•
China Merchants China Direct Investments
•
21 Jun 2024 11:58
CMCDI (133 HK): Kan Re-Elected. But Only Just
CMCDI remains cheap. Argyle is still buying. If small, illiquid names, with a activism angle are your forte, get involved.
David Blennerhassett
Follow
920 Views
Share
Previous
1
2
3
4
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x